Preclinical and Clinical Development of a Multi-Envelope, DNA-Virus-Protein (D-V-P) HIV-1 Vaccine

REFERENCES

• News in Brief. HIV vaccine failure prompts Merck to halt trial. Nature 2007; 449: 390
   PubMed Web of Science ®Google Scholar
• Murphy K., Travers P., Walport M. Janeway's Immunobiology. Garland Science, New York 2008
   Google Scholar
• Hammarlund E., Lewis M. W., Hansen S. G., Strelow L. I., Nelson J. A., Sexton G. J., Hanifin J. M., Slifka M. K. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9: 1131–1137
   PubMed Web of Science ®Google Scholar
• Li Y., Carroll D. S., Gardner S. N., Walsh M. C., Vitalis E. A., Damon I. K. On the origin of smallpox: Correlating variola phylogenics with historical smallpox records. Proc Natl Acad Sci USA 2007; 104: 15787–15792
   PubMed Web of Science ®Google Scholar
• Fenner F., Henderson D. A., Arita I., Jezek Z., Ladnyi I. D. Smallpox and its eradication. World Health Organization, GenevaSwitzerland 1988
   Google Scholar
• Clark H. F., Offit P. A., Plotkin S. A., Heaton P. M. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) human rotavirus reassortants. Pediatr Infect Dis J 2006; 25: 577–583
   PubMed Web of Science ®Google Scholar
• Hurwitz J. L., Slobod K. S., Lockey T. D., Wang S., Chou T. H., Lu S. Application of the polyvalent approach to HIV-1 vaccine development. Curr Drug Targets Infect Disord 2005; 5: 143–156
   Google Scholar
• Biagini R. E., Schlottmann S. A., Sammons D. L., Smith J. P., Snawder J. C., Striley C. A., MacKenzie B. A., Weissman D. N. Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin Diagn Lab Immunol 2003; 10: 744–750
   PubMedGoogle Scholar
• Preston B. D., Poiesz B. J., Loeb L. A. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168–1171
   PubMed Web of Science ®Google Scholar
• Roberts J. D., Bebenek K., Kunkel T. A. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242: 1171–1173
   PubMed Web of Science ®Google Scholar
• Sanabani S., Neto W. K., de Sa Filho D. J., Diaz R. S., Munerato P., Janini L. M., Sabino E. C. Full-length genome analysis of human immunodeficiency virus type 1 subtype C in Brazil. AIDS Res Hum Retroviruses 2006; 22: 171–176
   Google Scholar
• Barouch D. H., Kunstman J., Glowczwskie J., Kunstman K. J., Egan M. A., Peyerl F. W., Santra S., Kuroda M. J., Schmitz J. E., Beaudry K., Krivulka G. R., Lifton M. A., Gorgone D. A., Wolinsky S. M., Letvin N. L. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77: 7367–7375
   PubMedGoogle Scholar
• Berman P. W., Gray A. M., Wrin T., Vennari J. C., Eastman D. J., Nakamura G. R., Francis D. P., Gorse G., Schwartz D. H. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis 1997; 176: 384–397
   PubMedGoogle Scholar
• D'Costa S., Slobod K. S., Webster R. G., White S. W., Hurwitz J. L. Structural features of HIV envelope defined by antibody escape mutant analysis. AIDS Res Hum Retroviruses 2001; 17: 1205–1209
   Google Scholar
• White-Scharf M. E., Potts B. J., Smith L. M., Sokolowski K. A., Rusche J. R., Silver S. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 1993; 192: 197–206
   Google Scholar
• LaCasse R. A., Follis K. E., Trahey M., Scarborough J. D., Littman D. R., Nunberg J. H. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. Science 1999; 283: 357–362
   PubMed Web of Science ®Google Scholar
• Barnett S. W., Srivastava I. K., Ulmer J. B., Donnelly J. J., Rappuoli R. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect 2005; 7: 1386–1391
   Google Scholar
• LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Lanlois A. J., Dreesman G. R., Boswell R. N., Shadduck P., Holley L. H., Karplus M., Bolognesi D. P., Matthews T. J., Emini E. A., Putney S. D. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990; 249: 932–935
   PubMed Web of Science ®Google Scholar
• Javaherian K., Langlois A. J., LaRosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D., Matthews T. J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990; 250: 1590–1593
   PubMed Web of Science ®Google Scholar
• Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B. H., Bhattacharya T., Korber B. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354–2360
   PubMed Web of Science ®Google Scholar
• Conley A. J., Kessler J. A., II, Boots L. J., Tung J. S., Arnold B. A., Keller P. M., Shaw A. R., Emini E. A. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994; 91: 3348–3352
   PubMedGoogle Scholar
• Lockey T. D., Slobod K. S., Caver T. E., D'Costa S., Owens R. J., McClure H. M., Compans R. W., Hurwitz J. L. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. Immunol Res 2000; 21: 7–21
   Google Scholar
• Haynes B. F., Fleming J., St. Clair E. W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R. M., Plonk K., Staats H. F., Ortel T. L., Liao H. X., Alam S. M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308: 1906–1908
   PubMed Web of Science ®Google Scholar
• Wright P. F., Neumann G., Kawaoka Y. Orthomyxoviruses. Fields Virology, 5th Edition, D. M. Knipe, P. M. Howley. Williams and Wilkins, Lippincott, Philadelphia, PA 2008; 1671–1740
   Google Scholar
• Gerhard W., Yewdell J., Frankel M. E., Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 1981; 290: 713–717
   PubMed Web of Science ®Google Scholar
• Sealy R., Chaka W., Surman S., Brown S. A., Cresswell P., Hurwitz J. L. Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities. Clin Vaccine Immunol 2008; 15: 713–719
   Google Scholar
• Moudgil K. D., Sercarz E. E., Grewal I. S. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol Today 1998; 19: 217–220
   PubMedGoogle Scholar
• Kwong P. D., Wyatt R., Robinson J., Sweet R. W., Sodroski J., Hendrickson W. A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648–659
   PubMed Web of Science ®Google Scholar
• Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990; 345: 622–625
   PubMed Web of Science ®Google Scholar
• Hu S.-L., Abrams K., Barber G. N., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R., Benveniste R. E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255: 456–459
   PubMed Web of Science ®Google Scholar
• Polacino P., Stallard V., Klaniecki J. E., Montefiori D. C., Langlois A. J., Richardson B. A., Overbaugh J., Morton W. R., Benveniste R. E., Hu S. L. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol 1999; 73: 618–630
   PubMedGoogle Scholar
• Wyand M. S., Manson K., Montefiori D. C., Lifson J. D., Johnson R. P., Desrosiers R. C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999; 73: 8356–8363
   PubMed Web of Science ®Google Scholar
• Wrin T., Crawford L., Sawyer L., Weber P., Sheppard H. W., Hanson C. V. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994; 7: 211–219
   Google Scholar
• Richman D. D., Wrin T., Little S. J., Petropoulos C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144–4149
   PubMed Web of Science ®Google Scholar
• Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938–1941
   PubMed Web of Science ®Google Scholar
• Cranage M. P., Whatmore A. M., Sharpe S. A., Cook N., Polyanskaya N., Leech S., Smith J. D., Rud E. W., Dennis M. J., Hall G. A. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997; 229: 143–154
   PubMed Web of Science ®Google Scholar
• Stephens E. B., Joag S. V., Atkinson B., Sahni M., Li Z., Foresman L., Adany I., Narayan O. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV(KU-1). Virology 1997; 234: 328–339
   Google Scholar
• Titti F., Sernicola L., Geraci A., Panzini G., Di Fabio S., Belli R., Monardo F., Borsetti A., Maggiorella M. T., Koanga-Mogtomo M., Corrias F., Zamarchi R., Amadori A., Chieco-Bianchi L., Verani P. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 1997; 78: 2529–2539, (Pt 10)
   PubMed Web of Science ®Google Scholar
• Chakraborty B., Valer L., De M. C., Soriano V., Quinones-Mateu M. E. Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Res Hum Retroviruses 2004; 20: 1026–1031
   Google Scholar
• Gonzales M. J., Delwart E., Rhee S. Y., Tsui R., Zolopa A. R., Taylor J., Shafer R. W. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis 2003; 188: 397–405
   Google Scholar
• Altfeld M., Allen T. M., Yu X. G., Johnston M. N., Agrawal D., Korber B. T., Montefiori D. C., O'Connor D. H., Davis B. T., Lee P. K., Maier E. L., Harlow J., Goulder P. J., Brander C., Rosenberg E. S., Walker B. D. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002; 420: 434–439
   PubMed Web of Science ®Google Scholar
• Rickinson A. B., Kieff E. Epstein-Barr virus. Fields Virology, D. M. Knipe, P. M. Howley, D. E. Griffin, M. A. Martin, R. A. Lamb, B. Roizman, S. E. Straus. Lippincott Williams and Wilkins, Philadelphia, PA 2001; 2575–2627
   Google Scholar
• Goldman G. S. Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage. Vaccine 2003; 21: 4243–4249
   Google Scholar
• Slobod K. S., Coleclough C., Bonsignori M., Brown S. A., Zhan X., Surman S., Zirkel A., Jones B. G., Sealy R. E., Stambas J., Brown B., Lockey T. D., Freiden P. J., Doherty P. C., Blanchard J. L., Martin L. N., Hurwitz J. L. HIV vaccine rationale, design and testing. Curr HIV Res 2005; 3: 107–112
   PubMedGoogle Scholar
• Stambas J., Brown S. A., Gutierrez A., Sealy R., Yue W., Jones B., Lockey T. D., Zirkel A., Freiden P., Brown B., Surman S., Coleclough C., Slobod K. S., Doherty P. C., Hurwitz J. L. Long-lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 2005; 23: 2454–2464
   Google Scholar
• Richmond J. F. L., Mustafa F., Lu S., Santoro J. C., Weng J., O'Connell M., Fenyo E. M., Hurwitz J. L., Montefiori D. C., Robinson H. L. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997; 230: 265–274
   PubMedGoogle Scholar
• Caver T. E., Lockey T. D., Srinivas R. V., Webster R. G., Hurwitz J. L. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999; 17: 1567–1572
   Google Scholar
• Ljungberg K., Rollman E., Eriksson L., Hinkula J., Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002; 302: 44–57
   PubMedGoogle Scholar
• Kong W.-P., Huang Y., Yang Z.-Y., Chakrabarti B. K., Moodie Z., Nabel G. J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003; 77: 12764–12772
   PubMedGoogle Scholar
• Cho M. W., Kim Y. B., Lee M. K., Gupta K. C., Ross W., Plishka R., Buckler-White A., Igarashi T., Theodore T., Byrum R., Kemp C., Montefiori D. C., Martin M. A. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 2001; 75: 2224–2234
   PubMed Web of Science ®Google Scholar
• Zhan X., Slobod K. S., Surman S., Brown S. A., Coleclough C., Hurwitz J. L. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine 2004; 22: 1206–1213
   PubMedGoogle Scholar
• Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70: 427–444
   PubMed Web of Science ®Google Scholar
• Weber J., Fenyo E. M., Beddows S., Kaleebu P., Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 1996; 70: 7827–7832
   PubMedGoogle Scholar
• Zhan X., Martin L. N., Slobod K. S., Coleclough C., Lockey T. D., Brown S. A., Stambas J., Bonsignori M., Sealy R. E., Blanchard J. L., Hurwitz J. L. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005; 23: 5306–5320
   PubMedGoogle Scholar
• Zolla-Pazner S., Gorny M. K., Nyambi P. N., VanCott T. C., Nadas A. Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV. J Virol 1999; 73: 4042–4051
   PubMedGoogle Scholar
• Azizi A., Anderson D. E., Torres J. V., Ogrel A., Ghorbani M., Soare C., Sandstrom P., Fournier J., Az-Mitoma F. Induction of broad-cross subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol 2008; 180: 2174–2186
   PubMedGoogle Scholar
• Dong X. N., Wu Y., Chen Y. H. The neutralizing epitope ELDKWA on HIV-1 gp41: Genetic variability and antigenicity. Immunol Lett, 101: 81–86
   Google Scholar
• Chakrabarti B. K., Ling X., Yang Z. Y., Montefiori D. C., Panet A., Kong W. P., Welcher B., Louder M. K., Mascola J. R., Nabel G. J. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 2005; 23: 3434–3445
   PubMedGoogle Scholar
• Rollman E., Brave A., Boberg A., Gudmundsdotter L., Engstrom G., Isaguliants M., Ljungberg K., Lundgren B., Blomberg P., Hinkula J., Hejdeman B., Sandstrom E., Liu M., Wahren B. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect 2005; 7: 1414–1423
   PubMed Web of Science ®Google Scholar
• Pal R., Kalyanaraman V. S., Nair B. C., Whitney S., Keen T., Hocker L., Hudacik L., Rose N., Mboudjeka I., Shen S., Wu-Chou T. H., Montefiori D., Mascola J., Markham P., Lu S. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006; 348: 341–353
   PubMed Web of Science ®Google Scholar
• Hurwitz J. L., Lockey T. D., Jones B., Freiden P., Sealy R., Coleman J., Howlett N., Branum K., Slobod K. S. First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants. AIDS 2008; 22: 149–151
   PubMedGoogle Scholar
• Slobod K. S., Lockey T. D., Howlett N., Srinivas R. V., Rencher S. D., Freiden P. J., Doherty P. C., Hurwitz J. L. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004; 23: 106–110
   Google Scholar
• Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K. M., Tartaglia J., Caudrelier P., El Habib R., Klein M., Lazzarin A., Stablein D. M., Deers M., Corey L., Greenberg M. L., Schwartz D. H., Montefiori D. C. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 16: 2019–2035
   Google Scholar
• Lian Y., Srivastava I., Gomez-Roman V. R., Zur M. J., Sun Y., Kan E., Hilt S., Engelbrecht S., Himathongkham S., Luciw P. A., Otten G., Ulmer J. B., Donnelly J. J., Rabussay D., Montefiori D., van Rensburg E. J., Barnett S. W. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 2005; 79: 13338–13349
   Google Scholar
• Hosoi S., Borsos T., Dunlop N., Nara P. L. Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro. J Acquir Immunodefic Syn 1990; 3: 366–371
   Google Scholar
• Van Rompay K. K., Berardi C. J., Dillard-Telm S., Tarara R. P., Canfield D. R., Valverde C. R., Montefiori D. C., Cole K. S., Montelaro R. C., Miller C. J., Marthas M. L. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998; 177: 1247–1259
   PubMed Web of Science ®Google Scholar
• Louder M. K., Sambor A., Chertova E., Hunte T., Barrett S., Ojong F., Sanders-Buell E., Zolla-Pazner S., McCutchan F. E., Roser J. D., Gabuzda D., Lifson J. D., Mascola J. R. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 2005; 339: 226–238
   Google Scholar
• Burnet F. M. Poliomyelitis in the light of recent experimental work. Australia Department of Health, Victoria 1945, Health Bulletin.
   Google Scholar
• Pallansch M. A., Roos R. P. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, S. E. Straus. Lippincott Williams and Wilkins, Philadelphia, PA 2001; 723–775
   Google Scholar
• Hurwitz J. L., Zhan X., Brown S. A., Bonsignori M., Stambas J., Lockey T. D., Sealy R., Surman S., Freiden P., Jones B., Martin L., Blanchard J., Slobod K. S. HIV-1 vaccine development: Tackling virus diversity with a multi-envelope cocktail. Front Biosci 2008; 13: 609–620
   Google Scholar
• Zhan X., Slobod K. S., Surman S., Brown S. A., Lockey T. D., Coleclough C., Doherty P. C., Hurwitz J. L. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J Virol 2003; 77: 4231–4236
   Google Scholar
• Rencher S. D., Hurwitz J. L. Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3 and non-V3-specific antibodies. J Acquir Immunodefic Syn 1997; 16: 69–73
   Google Scholar
• Brown S. A., Slobod K. S., Surman S., Zirkel A., Zhan X., Hurwitz J. L. Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype. AIDS Res Hum Retroviruses 2006; 22: 188–194
   Google Scholar